An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma
The ongoing Phase 1 trial sponsored by University College London is evaluating a novel BCMA CAR T-cell therapy, both as a standalone treatment and in combination with a CD19 CAR, for patients with relapsed/refractory multiple myeloma. The market for multiple myeloma therapies is expanding, with increasing demand for innovative treatments due to the limitations of existing therapies. The dual-targeting approach may provide a competitive edge in efficacy and safety, addressing a significant unmet need in this patient population. The trial's success could position the sponsor favorably for future partnerships or commercialization opportunities, particularly in the context of advanced therapy medicinal products (ATMPs).
Indication: Multiple Myeloma
Modality: protein therapy
Target: BCMA (B-cell maturation antigen) and CD19
Sponsor: University College, London
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCMA (B-cell maturation antigen) and CD19
View original source fields
Condition raw: Multiple Myeloma
Condition normalized: Multiple Myeloma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: BCMA (B-cell maturation antigen) and CD19
Target normalized: BCMA (B-cell maturation antigen) and CD19